Clinical Trials by Tumor Biology & Microbiology Program Members

Clinical Trials by Tumor Biology & Microbiology Program Members

Dr. Vaishampayan is conducting a pilot trial of oral cabozantinib/ XL184 in metastatic castrate resistant prostate cancer to explore the changes in bone and tumor imaging related pathways (KCI Protocol # 2011-185). It is now closed to accrual, but research related intervention and follow up are ongoing.

In collaboration with Dr. Gadgeel (MT), Dr. Hillman studies the effects of soy isoflavones on decreasing or preventing the inflammation associated with lung cancer radiation therapy (Hillman G, J Thorac Oncol, 2013). Based on this study, there is a PI-initiated clinical trial of Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients with Stage IIIA-IIIB Non-Small Cell Lung Cancer (KCI protocol #2013-021).

Drs. Vaishampayan and Heath (MT) are co-investigators on a multi-institutional study to evaluate immune responses to Sipuleucel-T in African American men and non-African American men with castrate resistant prostate cancer (Protocol #2013-108) which is a multi-center grant involving the Prostate Cancer Clinical Trials consortium [(Barbara Ann Karmanos Cancer Center (Wayne State University), Carbone Cancer Center (University of Wisconsin), Dana-Farber Cancer Institute (Harvard Medical School), Duke Cancer Institute, Fred Hutchinson Cancer Research Center (University of Washington), Helen Diller Family Comprehensive Cancer Center (University of California San Francisco), Knight Cancer Institute (Oregon Health and Science University), MD Anderson Cancer Center (University of Texas), Memorial Sloan Kettering Cancer Center, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins University), University of Chicago Comprehensive Cancer Center, University of Medicine and Dentistry of New Jersey, and Henry Ford Health System. 

More Information

For more information on these trials, or to view all clinical trials available at Karmanos Cancer Institute, please click here

The Latest From Karmanos Cancer Institute

News

IN THE NEWS: Searching for support

Cancer Wellness "The Karmanos Men's Support Group is now like a family to me that meets all my criteria," said Robert Brooks, a multiple myeloma s...

Read More

Karmanos Cancer Institute first to receive innovative, FDA-approved SoftVue™ Breast Imaging System

The Barbara Ann Karmanos Cancer Institute , the world-renowned, Detroit-based National Cancer Institute-Designated Comprehensive Cancer Center, is...

Read More

Hayley Thompson, Ph.D., recognized for her work with LGBT community

"...to be acknowledged by LGBT Detroit for community service is incredibly meaningful."   LGBT Detroit, an organization that works to increas...

Read More
News

ACS CAN Michigan Candid Connection, June 2022 - Cancer Survivorship

Listen Now

How a preemptive cancer screening helped save this doctor’s life

Listen Now

Eliminating health disparities around multiple myeloma

Listen Now